Sam M Lockhart,Milan Muso,Ilona Zvetkova,Brian YH Lam,Alessandra Ferrari,Erik Schoenmakers,Katie Duckett,Jack Leslie,Beatriz Romartínez-Alonso,John Tadross,Raina Jia,Eugene J. Gardner,Katherine Kentistou,Yajie Zhao,Felix Day,Alexander Mörseburg,Kara Rainbow,Debra Rimmington,Matteo Mastantuoni,James Harrison,Meritxell Nus,Khalid Guma’a,Sam Sherratt-Mayhew,Xiao Jiang,Katherine R Smith,Dirk S Paul,Ben Jenkins,Albert Koulman,Maik Pietzner,Claudia Langenberg,Nick Wareham,Giles S Yeo,Krishna Chatterjee,John Schwabe,Fiona Oakley,Derek Mann,Peter Tontonoz,Tony Coll,Ken Ong,John R.B. Perry,Stephen O’Rahilly

Abstract:The nuclear receptor Liver X Receptor-α (LXRα) activates lipogenic gene expression in hepatocytes. Its inhibition has therefore been proposed as a strategy to treat metabolic-dysfunction-associated steatotic liver disease (MASLD). In order to understand the impact of reducing LXRα activity on human health we first examined the association between the carriage of rare loss of function mutations in (encoding LXRα) and metabolic and hepatic phenotypes. We identified 63 rare predicted damaging variants in the ligand binding domain of LXRα in 454,787 participants in UK Biobank. On functional characterisation, 42 of these were found to be severely impaired. Consistent with loss of the lipogenic actions of LXRα, carriers of damaging mutations in LXRα had reduced serum triglycerides (ß=-0.13 s.d. ±0.03, P=2.7x10 , N(carriers)=971). Surprisingly, these carriers also had elevated concentrations of serum liver enzymes (e.g. ALT: ß=0.17s.d. ±0.03, P=1.1x10 , N(carriers)=972) with a 35% increased risk of clinically significant elevations in ALT (OR=1.32, 95%CI:1.15-1.53, P=1.2x10 , N(carriers)=972), suggestive of hepatotoxicity. We generated a knock-in mouse carrying one of the most severely damaging mutations ( p.W441R) which we demonstrated to have dominant negative properties. Homozygous knock-in mice rapidly developed severe hepatitis and fibrotic liver injury following exposure to western diet despite markedly reduced steatosis, liver triglycerides and lipogenic gene expression. This phenotype was completely rescued by viral over-expression of wildtype LXRα specifically in hepatocytes, indicating a cell-autonomous effect of the mutant on hepatocyte health. While homozygous LXRα knockout mice showed some evidence of hepatocyte injury under similar dietary conditions, the phenotype of the LXRα mouse was much more severe, suggesting that dominant negative mutations that actively co-repress target genes can result in pathological impacts significantly more severe than those seen with simple absence of the receptor. In summary, our results show that loss of function mutations in LXRα occur in at least 1/450 people and are associated with evidence of liver dysfunction. These findings implicate LXRα in the maintenance of human liver health, identify a new murine model of rapidly progressive fibrotic liver disease and caution against LXR antagonism as a therapeutic strategy for MASLD.

260-LB: The Effect of LXR Activation on Liver Metabolism and Diet-Induced Steatohepatitis in Mice

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis

<strong><b></b></strong>Impaired Adipose Tissue Expansion Caused by LXR Activation is Associated with Insulin Resistance in HFD Mice

Activation of Liver X Receptors Attenuates Endotoxin-Induced Liver Injury in Mice with Nonalcoholic Fatty Liver Disease

Activation of Liver X Receptor Improves Glucose Tolerance Through Coordinate Regulation of Glucose Metabolism in Liver and Adipose Tissue

Coadministration Of A Liver X Receptor Agonist And A Peroxisome Proliferator Activator Receptor-Alpha Agonist In Mice: Effects Of Nuclear Receptor Interplay On High-Density Lipoprotein And Triglyceride Metabolism In Vivo

Tu1660 HEPATIC P53-PXR-SCD1 AXIS PARTICIPATES IN NAFLD PROCESS

The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice

LXR Agonist T0901317′s Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice

Damaging mutations in LXRα uncouple lipogenesis from hepatotoxicity and implicate hepatic cholesterol sensing in human liver health

LXR regulation of adipose tissue inflammation during obesity is associated with dysregulated macrophage function

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease

A Novel Mutation in LXRalpha Uncovers a Role for Cholesterol Sensing in Limiting Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease

Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice

LRG Ameliorates Steatohepatitis by Activating the AMPK/mTOR/SREBP1 Signaling Pathway in C57BL/6J Mice Fed a High‑fat Diet.

Liver X receptor activation increases hepatic fatty acid desaturation by the induction of SCD1 expression through an LXRα-SREBP1c-dependent mechanism.

Untangling the inflammatory responses of liver x receptor (LXR) activation in human macrophages